Navigation Links
NexGen Biofuels Ltd. Announces Trading on OTC Bulletin Board
Date:3/20/2008

WESLEY CHAPEL, Florida, March 20 /PRNewswire-FirstCall/ -- NexGen Biofuels Ltd. (OTC:NXGNF) announced today that effective as of March 17, 2008, its ordinary shares have been approved for quotation on the OTC-Bulletin Board under the symbol NXGNF.

NexGen is a development stage company that is currently seeking to develop and/or acquire ethanol and bio-diesel plants and blending assets in the United States.

For More Information On NexGen Biofuels, Visit http://www.nexgenbiofuels.net.

Safe Harbor: This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward looking statement made by or on behalf of NexGen Biofuels Ltd. Readers are referred to the documents filed by the company with the Securities And Exchange Commission, specifically the form 8-K/A filed on February 12, 2008 that identifies important risks which could cause actual results to differ from those contained in the forward looking statements.

Contact: Eran Rotem CFO

+972-3-9277232


'/>"/>
SOURCE NexGen Biofuels Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
2. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
3. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
4. Healthcare Technologies Ltd. Announces the Change of its Name to "NexGen Biofuels Ltd"
5. NexGen Biofuels Ltd. (Nasdaq: NXGN) Announces Receipt of Nasdaq Delisting Determination
6. N.C. Takes Biofuels Leadership, Establishes New Endeavor With $5 Million State Appropriation
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
9. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)... , COLUMBUS, Ohio, Nov. 30 The...or one of the nation,s first minority business ear...n Cleveland December 3, is called "Transforming th...iness Early-Stage Capital Summit." It will feature...nority business leaders and local minority entrepr...
(Date:11/30/2009)... , KING OF PRUSSIA, Pa., Nov. 30 /PRNew... company specializing in interactive marketing se...today announced the launch of its HATCH Consultin.../hatch ). Aligning strategic experts across a ran...ing, the HATCH Consulting team is committed to gui...
(Date:11/30/2009)... , NEW YORK, Nov. 30 /PRNewswire-USNewswire/ -...search (MJFF) today announced $1.5 million in tota...potentially disease-modifying therapies for Parkin...Novel Approaches to Drug Discovery for Parkinson,s...lan Corporation, plc (NYSE: ELN ), a neuroscienc...
(Date:11/30/2009)... , BRIARCLIFF MANOR, N.Y., Nov. 30 /PRNew...y guidance document for the publication of company...line today by the British Medical Journal (BMJ). "...on of the importance of providing support and guid...cation of study results in the peer-reviewed medic...
Breaking Biology Technology:Ohio Capital Fund Announces Sponsorship of Minority Business Conference 2Cadient Interactive Announces the Launch of HATCH Consulting Services 2Cadient Interactive Announces the Launch of HATCH Consulting Services 3The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 3ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 2ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 3
...eb. 11 Caliper Life,Sciences, Inc. (Nasdaq: CALP...utsche Bank 2008 Small and Mid Cap Growth Conferen..., February 13 at 4:40 p.m. EST. Kevin,Hrusovsky, P...update on the,company,s business. The live webcast...reye/confLobby.zhtml?ticker=CALP&item_id=17485 ,73...
...s Potential New Short-Course Treatment Option for ...luding MRSA, CAMBRIDGE, Mass., Feb. 11 Targanta,...d today that it has,submitted a New Drug Applicati...(FDA) for its lead antibiotic candidate, oritavanc...otic candidate with potent,bactericidal (killing) ...
...e real-world clinical data on the PROMUS(TM) Stent...ration (NYSE: BSX ) today announced that the firs...(TM), ENdeavor(R) and CYpher(R)) European,registry...Olimus,-eluting,coronary stents. It will collect r...ic,s PROMUS(TM) Everolimus-Eluting Coronary Stent ...
Other Biology Technology:Targanta Submits Oritavancin New Drug Application 2Targanta Submits Oritavancin New Drug Application 3Targanta Submits Oritavancin New Drug Application 4Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents 2Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents 3Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents 4
(Date:11/30/2009)..., N.J. - The inaugural Global Conference on Syste...2009, in Washington, DC, focuses on the convergenc...f critical importance to society. , The goal...arch activity around targeted complex systems, exa...s topic includes Critical Infrastructure Systems, ...
(Date:11/30/2009)... obstacle to HIV research is the virus,s exquisite...cientists, traditional tools, like the humble lab ...a team of researchers writing in BioMed Central,s ...nious assault on this problem by creating a mouse ...ng infected with HIV. , George Kassiotis, from t...
(Date:11/30/2009)... is a colorless and odorless radioactive gas that ...dium is a product of uranium decay and is found in...s, and groundwater as well as building materials, ...ncentration is expressed as the amount of radiatio...ducts in a liter of air; thus the units are picocu...
Breaking Biology News(10 mins):First global conference on systems and enterprises at new Stevens location, Washington, DC, Dec. 3-4 2A reductionist approach to HIV research 2Health Physics Society recommends considering action for indoor radon below current guidelines 2Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 1Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 2Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 3Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 4Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 5Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 6Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 7Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 1Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 2Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 3Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 4Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 5Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 6Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 7Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 8Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 9Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 10Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 11Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 12Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 13Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 14Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 15Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 16Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 17Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 18Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 19Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 20Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 21Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 22Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 23Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 24Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 25Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 26Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 27Safe Ozone Levels May Not Be for Some 52829 1Safe Ozone Levels May Not Be for Some 52829 2
...ts have combined two molecules that occur naturall...es solar energy to split water into hydrogen and o...l of the American Chemical Society. , This molecu...hydrogen gas, providing an alternative to electrol...o its constituent parts. The breakthrough may pave...
...t real-data study of sharks harvested for their va...many as 73 million sharks are killed each year wor...nally by the United Nations, according to a paper ...dition of Ecology Letters. , "The shark fin trade...nto fin auction records and convert from fin sizes...
...ts and medical researchers for the first time have...measures in real time the level of damage to the s...ts suggest that women,s skin ages faster than men,...s Letters, a journal of the Optical Society of Ame... fabric of the deeper layers of the skin, combinin...
Other Biology News:Genetically engineered blood protein can be used to split water into oxygen and hydrogen 2Triple threat: World fin trade may harvest up to 73 million sharks per year 2German researchers develop first non-invasive test to measure skin aging 2German researchers develop first non-invasive test to measure skin aging 3
Rabbit Anti-Methionine Aminopeptidase 2 Polyclonal Antibody, Unconjugated from Abcam
Anti-FKHR, phospho (Thr24) / FKHRL1, phospho (Thr32) Antibody, Unconjugated from Cell Signaling Technology
Mouse Anti-Ricin communis Monoclonal Antibody, Unconjugated, Clone CP23 from Abcam
Kinase Buffer (10X) from Cell Signaling Technology
Biology Products: